Highlights Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
4.83 ^USD	+1.68%		-2.42%	+11.55%

05-02	Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02	Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	05-02	CI
Puma Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	03-20	MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	03-20	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	02-29	CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	02-29	MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	02-13	CI
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	12-11	CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.17, vs. Street Est of $0.14	11-02	MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023	11-02	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting	14/10/23	CI
Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation	21/09/23	DJ
Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer	08/08/23	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q2 EPS $0.10, vs. Street Est of $0.07	03/08/23	MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023	03/08/23	CI
Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting	04/06/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Highlights

Filters